executive team  about  momenta pharmaceuticals inc please enable js about about•executive team executive team craig a wheeler president and chief executive officer jim anderson phd senior vice president pharmaceutical science santiago arroyo md phd senior vice president development and chief medical officer joann beltramello senior vice president human resources ian d fier senior vice president program and alliance leadership ganesh v kaundinya phd senior vice president chief scientific officer and cofounder young kwon phd senior vice president corporate development and strategy bruce a leichersenior vice president general counsel and secretary anthony manning phdsenior vice president research scott m storersenior vice president chief financial officer and treasurer     craig a wheelerpresident and chief executive officer mr wheeler joined momenta as ceo in september of  he led the company through the launch of its first complex drug products including the first generic versions of lovenox® and oncedaily copaxone® he has overseen the company’s growth into the diversified business it is today in  he was an ey entrepreneur of the year regional award winner in may  the boston globe named momenta the number one company in their annual globe  survey of top performing companies prior to joining momenta mr wheeler was president of chiron biopharmaceuticals where during his fiveyear tenure the pharmaceutical division’s global sales more than doubled before that he was a senior member of the boston consulting group’s health care practice and worked extensively in the health care sector he began his career at merck’s msdrl research unit  mr wheeler is currently a member of the board of directors of amicus therapeutics as well as the generic pharmaceutical association gpha where he previously served as chairman from  to february   he also previously served as the chairman of the board of avanir pharmaceuticals where he helped oversee the transition of the company from a researchbased platform to a fully integrated cns pharmaceutical company until  when it was acquired by otsuka pharmaceuticals for  billion   jim anderson phdsenior vice president pharmaceutical science dr anderson joined momenta pharmaceuticals in march of  he is responsible for the establishment of manufacturing processes and associated controls supply of clinical materials transfer of commercial processes to external cmo partners and preparation of cmc regulatory submissions for all of momenta’s products that are in development dr anderson initially joined momenta as the head of the analytical development organization prior to momenta he was the director of pharmacy and analytical development at bristolmyers squibb medical imaging where he led project teams for new drug product programs in total dr anderson has approximately  years of cmc development experience santiago arroyo md phdsenior vice president development and chief medical officer dr arroyo joined momenta in june of   he is responsible for preclinical and clinical development and regulatory affairs he joins momenta from boston pharmaceuticals where he was chief medical officer previously he was senior vice president head of clinical research and chief medical officer of biotherapeutics and pharmatherapeutics at pfizer inc in the areas of cardiovascular and metabolism pain neuroscience regenerative medicine and rare diseases he was previously therapeutic area head for neurosciences discovery medicine and clinical pharmacology at bristolmyers squibb and neurology global therapeutic area head for eisai global clinical development dr arroyo was an instructor in neurology at the johns hopkins hospital and associate professor of neurology and director of the epilepsy program at the medical college of wisconsin and at the hospital clinic of barcelona spain dr arroyo received his medical degree from the autonomous university of madrid and his phd from the university of barcelona spain joann beltramellosenior vice president human resources ms beltramello joined momenta in october of  she was previously the chief human resources officer at multiplan a provider of health care cost management solutions with over  employees conducting business in all fifty states in this role she was responsible for all human resource operations including strategy policies and program development prior to joining multiplan she held senior human resources roles at private healthcare systems inc oxford global resources inc and randstad north america ian d fier senior vice president program and alliance leadership mr fier joined momenta in october of  he was previously vice president of clinical affairs at biotransplant inc where he led a clinical development group responsible for the development and commercialization of both antibodybased therapeutics and medical devices prior to that he held positions in product development and project management at hoechstroussel now sanofi aventis astra usa and the medicines company and was involved with the development and launch of several successful products mr fier received his bs from tufts university and a mba in heath care management from boston university ganesh v kaundinya phdsenior vice president chief scientific officer and cofounder dr kaundinya is one of momentas founders since inception dr kaundinya has played a key role in defining the business and scientific strategy and in building and leading the research organization prior to founding momenta dr kaundinya was a member of the mit faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology  he also served as the director of bioinformatics for the consortium for functional glycomics a multimilliondollar nih initiative to study the role of complex sugars in biology young kwon phdsenior vice president corporate development and strategy dr kwon joined momenta in january of  at momenta he is responsible for driving business and corporate development strategy aimed at achieving momenta’s corporate objectives these objectives include further developing our biosimilars and novel drug businesses through strategic transactions like those with baxter healthcare virdante pharmaceuticals and others he was previously senior director of business development at biogen idec where he led corporate development activities including evaluation of mergers and acquisitions joint ventures and other strategic transactions prior to that he identified and invested in earlystage life science companies at advanced technology ventures he has coauthored numerous peerreviewed publications in the area of neurobiology bruce a leichersenior vice president general counsel and secretary mr leicher joined momenta in july of  he was previously senior vice president and general counsel at altus pharmaceuticals inc and also served as general counsel and in senior legal positions at antigenics inc millennium pharmaceuticals inc curis inc genetics institute inc and wyeth mr leicher brings significant legal expertise in research and product development product commercialization and launch corporate finance and partnering transactions intellectual property law and licensing corporate governance and litigation in private practice he served as the cochair of the life sciences practice group at hill and barlow and was an attorney at hale and dorr and butler and binion anthony manning phdsenior vice president research dr manning joined momenta in january  he is responsible for research and driving the discovery of novel products since joining momenta his teams have advanced three novel autoimmune drugs m m and hsivig into development and implemented a research engine to discover novel personalized therapies based on patient biocharacterization prior to momenta dr manning was vice president and head of immunology research for biogen idec inc before that he was vice president and global head of inflammation autoimmunity and transplantation research at roche pharmaceuticals dr manning holds a phd from the university of otago new zealand and has authored more than  peerreviewed publications and patents in the fields of signal transduction autoimmune diseases and drug discovery scott m storersenior vice president chief financial officer and treasurer  mr storer joined momenta in november  as senior vice president and chief financial officer   at momenta he is responsible for finance accounting investor relations information technology and facilities  prior to joining momenta mr storer was senior vice president finance at baxalta inc following its spinout from baxter international in july  before that mr storer held several positions with baxter most recently serving as vice president of bioscience finance where he provided financial leadership internal controls and business partnership to the bioscience us commercial organization global manufacturing rd business development and all support functions mr storer began his work at baxter as a financial analyst in    last updated  mnta ganesh venkataraman kaundinya insider trades for momenta pharmaceuticals inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close momenta pharmaceuticals inc nasdaq mnta go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus momenta pharmaceuticals inc after hours  quotes are delayed by  min jul    pm mnta quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual ganesh venkataraman kaundinya dr ganesh v kaundinya is chief scientific officer  senior vpresearch at momenta pharmaceuticals inc dr kaundinya was previously employed as bioinformatics director by consortium for functional glycomics and a memberresearch faculty by harvard university he received his graduate degree from the massachusetts institute of technology and a doctorate degree from the massachusetts institute of technology transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr craig a wheeler president ceo  class ii director mr scott m storer chief financial officer  senior vice president dr santiago arroyo chief medical officer  senior vpdevelopment dr ganesh venkataraman kaundinya chief scientific officer  senior vpresearch dr young t kwon vice presidentcorporate development  strategy dr james anderson vice presidentanalytical development ms barbara j rosengren vice presidentstrategic product development mr ian d fier vice presidentprogram  project management mr corey n fishman director dr steven c gilman director ms sarah carmody investor relations contact ms joann beltramello senior vice presidenthuman resources mr bruce a leicher secretary senior vp  general counsel mr james r sulat chairman dr josecarlos gutiérrezramos director dr georges gemayel director dr thomas paul koestler independent class iii director mr bruce l downey independent class i director dr elizabeth stoner independent class iii director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ganesh venkataraman kaundinya  cofounder at momenta pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink ganesh venkataraman kaundinya cofounder at momenta pharmaceuticals inc overview in the news relationships paths education career history investments public holdings ganesh venkataraman kaundinya cofounder at momenta pharmaceuticals inc overview age  born  notable companies momenta pharmaceuticals inc number of relationships this person is connected to  people in the news see more pr newswire september   momenta pharmaceuticals exercises option to acquire novel antibody program from anaptysbio business wire august   bioprocess international bpi  adds new focus on early stage biologics and companies relationships see details craig a wheeler president  chief executive officer at momenta pharmaceuticals inc scott m storer senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc ram sasisekharan scientific founder at visterra inc richard p shea chief financial officer  treasurer at syndax pharmaceuticals inc robert s langer cofounder at moderna therapeutics inc john k clarke cofounder at cardinal partners bruce a leicher former general counsel senior vice president  secretary at momenta pharmaceuticals inc alan crane cofounder at arsia therapeutics bruce l downey partner at newspring capital jim sulat professional at valneva se see  more listings with relsci professional start my free trial ➤ see  more paths to ganesh venkataraman kaundinya ganesh venkataraman kaundinya you connections via relationship science ganesh venkataraman kaundinya sync your contacts to see how you can connect with ganesh venkataraman kaundinya start my free trial ➤ see more educational background graduate degree  massachusetts institute of technology massachusetts institute of technology mit is a private research university located in cambridge massachusetts united states mit has five schools and one college containing a total of  academic departments with a strong emphasis on scientific engineering and technological education and research founded in  in response to the increasing industrialization of the united states the institute used a polytechnic university model and stressed laboratory instruction mit was elected to the association of american universities in  career history cofounder   current momenta pharmaceuticals inc momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs bioinformatics director    consortium for functional glycomics memberresearch faculty    harvard university harvard was established in  and it is the oldest institution of higher education in the united states the university which is based in cambridge and boston massachusetts has an enrollment of over  degree candidates including undergraduate graduate and professional students the university has twelve degreegranting schools in addition to the radcliffe institute for advanced study faculty member prior massachusetts institute of technology massachusetts institute of technology mit is a private research university located in cambridge massachusetts united states mit has five schools and one college containing a total of  academic departments with a strong emphasis on scientific engineering and technological education and research founded in  in response to the increasing industrialization of the united states the institute used a polytechnic university model and stressed laboratory instruction mit was elected to the association of american universities in  investments details hidden momenta pharmaceuticals inc momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations ganesh venkataraman kaundinya is affiliated with momenta pharmaceuticals inc consortium for functional glycomics harvard university massachusetts institute of technology youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ kaundinya ganesh venkataraman top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active kaundinya ganesh venkataraman • cambridge ma how do i update this listing kaundinya ganesh venkataraman is based out of cambridge whalewisdom has at least  insider transactions form  in our database for kaundinya ganesh venkataraman summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from kaundinya ganesh venkataraman enter your email address below and choose submit your email cancel contact info kaundinya ganesh venkataraman co momenta pharmaceuticals inc cambridge ma     business phone   sec sic codebiological products no disgnostic substances recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free kaundinya ganesh venkataraman  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address co momenta pharmaceuticals inc  west kendall street cambridge ma   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg sretswins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vmdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vmdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vmdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsdmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vmdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagkaundinya ganesh venkataramanmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsdmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vmdd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vs  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vs  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vs  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsmd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vs  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vs  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsam  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosvpreses  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosenior vsd  mntamomenta pharmaceuticals incdehealthbioprdbiological products no diagvenkataraman ganeshmaosvpresesmd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved txt   hdrsgml    accession number  conformed submission type  public document count  conformed period of report  filed as of date  date as of change  issuer company data company conformed name momenta pharmaceuticals inc central index key  standard industrial classification biological products no diagnostic substances  irs number  state of incorporation de fiscal year end  business address street   west kendall street city cambridge state ma zip  business phone   mail address street   west kendall street city cambridge state ma zip  reportingowner owner data company conformed name kaundinya ganesh venkataraman central index key  filing values form type  sec act  act sec file number  film number  mail address street  co momenta pharmaceuticals inc street   west kendall street city cambridge state ma zip  former name former conformed name venkataraman ganesh date of name change    edgarxml form   x     momenta pharmaceuticals inc mnta  kaundinya ganesh venkataraman co momenta pharmaceuticals inc  west kendall street cambridge ma      senior vp research common stock   s    d  d common stock   s    d  d this sale was effected pursuant to a rule b trading plan adopted by the reporting person on january   reflects  additional shares sold by the reporting person on may   that were inadvertently not reported as sold in the reporting persons form  filed on may   s marie t washburn as attorney in fact